

CVR Medical Announces Independent Report on Clinical Trial Results from Thomas Jefferson University Hospital

Vancouver, British Columbia--(Newsfile Corp. - June 29, 2017) - CVR Medical Corp. (TSXV: CVM) (FSE: B3BN) (OTCQB: CRRVF) ("CVR Medical") is pleased to announce that Thomas Jefferson University Hospital — Jefferson Clinical Research Institute has issued an initial trial report, summarizing the clinical trial progress of the Carotid Stenotic Scan (CSS) under the supervision of Principal Investigator Dr. David Whellan MD, MHS, FACC, FAHA.

Dr. Whellan commented, "The ENTICES (Evaluation of a Novel Technique to Investigate CAS piezo-Electric Sensors) Study, which is studying the CVR's Carotid Stenotic Scan (CSS) against current ultrasound technology, continues to enroll at a robust pace. The Jefferson Clinical Research Institute currently has data on over 125 within the study. A major factor in the successful enrollment has been the ease at which CSS data can be acquired, which allows participants to have test studies performed quickly. We look forward to completing enrollment and having results to share."

To view the full report, please go to <http://cvrmed.com/wp-content/uploads/2017/06/Clinical-trial-report.pdf>.

The Evaluation of a Novel Technique to Investigate CAS piezo-Electric Sensors Study

Principal Investigator

David J. Whellan, M.D., M.H.S., F.A.C.C., F.A.H.A.
James C. Wilson Professor of Medicine
Associate Provost for Clinical Research, Thomas Jefferson University
Associate Dean for Clinical Research, Sidney Kimmel Medical College
Executive Director, Jefferson Clinical Research Institute
1015 Chestnut Street, Suite 317
Philadelphia, PA 19107
Telephone: 215-955-2007. Fax: 215-503-0019
Email: david.whellan@jefferson.edu

Co-Investigator

Suzanne Adams RN MPH
Director, Clinical Operations/Education
Jefferson Clinical Research Institute
Program Director, MSCR
College of Biomedical Sciences
1015 Chestnut Street, Suite 317
Philadelphia, PA 19107
Telephone: 215-955-8848. Fax: 215-503-7420
Email: suzanne.adams@jefferson.edu

This is the first study evaluating a novel technology, Carotid Stenotic Scan (CSS), developed by the sponsor, CVR Global. The overall objectives of this study are to demonstrate that the CSS can accurately detect significant carotid artery stenosis, a known risk factor for stroke. A secondary objective is to relate changes in CSS signal to different degrees of stenosis. We obtain a “proof of concept” if the device correlates strongly with the established classification of atherosclerotic carotid disease derived various imaging modalities including magnetic resonance and computer tomographic angiography, conventional angiography, or carotid ultrasound.

Carotid duplex ultrasound uses B-mode ultrasound imaging and Doppler ultrasound to detect focal increases in blood flow velocity indicative of high grade carotid stenosis. It is noninvasive, safe, and relatively inexpensive. Compared with intra-arterial cerebral angiography for detecting a significant stenosis of the internal carotid artery, ultrasound has a sensitivity of 81 to 98 percent and a specificity of 82 to 89 percent.

The results presented here represent the first 109 carotid ultrasound subjects’ testing results for the primary objective, to assess the association between carotid artery stenosis as measured by CSS and carotid ultrasound.

Table 1 reports the demographic characteristics for the first set of subjects, including the hospital-based location of the Radiology ultrasound testing.

Table 2 reports the Enrollment metrics to date.

Table 3 reports the measurement values for the Left and Right carotid arteries as reported by the CSS device and by radiology-reported clinical ultrasound exam.

Table 1 Characteristics of Subjects Consented for CSS / CVR Global Study (n=109)

Variable	n (%)
Female	51 (47)
BMI (m±SD)	28.1 ± 5.96
Age (m±SD)	67.2 ± 13.6
Race	
White	78 (71.56)
Black	28 (25.70)
Other	3 (2.75)
Medical History	
Ischemic Heart Disease	21 (19.27)
Myocardial Infarction	17 (15.60)
Heart Failure	6 (5.50)
Peripheral Arterial Disease	13 (11.93)
TIA	12 (11.01)
Stroke	15 (13.76)
Diabetes	25 (22.94)
Hypertension	70 (64.22)
Hyperlipidemia	60 (55.05)
COPD	10 (9.17)
Enrollment Location	
General Radiology	64 (58.72)
Vascular Radiology	34 (28.44)
Inpatient	14 (12.84)

To view an enhanced version of Page 2 of the Study, please visit:
http://orders.newsfilecorp.com/files/1933/27717_a1498750123177_76.jpg

Table 2 Enrollment Metrics

Milestone	Date
1 st patient Enrolled	2/3/2017
Exclusion Criteria Revised to include Pre/Post-op Subjects	5/8/2017
Most Recent Patient Included in Analysis Enrolled	6/8/2017
Overall Enrollment Rate	6.06 pts per week
Enrollment Rate before Exclusion Criteria Change	4.84 pts per week
Enrollment Rate after Exclusion Criteria Change	9.94 pts per week

Table 3 CSS and Clinical Exam Reported Values

Left Carotid Results	
CSS Reported Result Left Carotid (m±SD)	30.30 ± 21.46
CSS Results Left Carotid (Categorical)	
<50% Stenosis	87 (79.82)
50-69% Stenosis	17 (15.60)
70-99% Stenosis	5 (4.59)
Clinical Exam Results Left Carotid (Categorical)	
<50% Stenosis	93 (85.32)
50-69% Stenosis	8 (7.34)
70-99% Stenosis	4 (3.67)
>99% Stenosis	2 (1.83)
Not Reported	2 (1.83)
Right Carotid Results	
CSS Reported Result Right Carotid (m±SD)	24.53 ± 17.95
CSS Results Right Carotid (Categorical)	
<50% Stenosis	102 (93.58)
50-69% Stenosis	5 (4.59)
70-99% Stenosis	2 (1.83)
Clinical Exam Results Right Carotid (Categorical)	
<50% Stenosis	93 (85.32)
50-69% Stenosis	12 (11.01)
70-99% Stenosis	2 (1.83)
>99% Stenosis	1 (0.92)
Not Reported	1 (0.92)

To view an enhanced version of Page 3 of the Study, please visit:
http://orders.newsfilecorp.com/files/1933/27717_a1498750123724_85.jpg

For additional information on the organization, leadership, and current news please visit the company website at www.CVRMed.com.

About CVR Medical

CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the "Joint Venture"). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.

On behalf of the Board:

(signed) "Peter Bakema"
 CEO, President & Director

For further information contact:

Brisco Capital Partners Corp.
 Scott Koyich, President
 Telephone: (403) 262-9888

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future

performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.